Bryostatin analog: improving on Nature’s design

Dale Boger

doi:10.18632/oncotarget.460

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access, biweekly journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing OncoTarget.

From January 1, 2021 Oncotarget is a biweekly journal that is published on Tuesday.

Request Conference Sponsorship

Editorial Comments:

Bryostatin analog: improving on Nature’s design

Dale Boger _

PDF | HTML | How to cite | Order a Reprint

Oncotarget. 2012; 3:116-117. https://doi.org/10.18632/oncotarget.460

Metrics: PDF 1333 views | HTML 1642 views | ?

Abstract

Commentary on: Dechristopher B et al. “Picolog,” a synthetically-available bryostatin analog, inhibits growth of MYC-induced lymphoma in vivo. Oncotarget 2012; 3: 58-66.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 460

Subscribe to TOC Alerts

Editorial Comments:

Bryostatin analog: improving on Nature’s design

Abstract